tert-butyl 4-(4-benzyloxyphenyl)piperazine-1-carboxylate | 943035-30-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(4-benzyloxyphenyl)piperazine-1-carboxylate
• 英文别名: Tert-butyl 4-(4-(benzyloxy)phenyl)piperazine-1-carboxylate；tert-butyl 4-(4-phenylmethoxyphenyl)piperazine-1-carboxylate
• CAS: 943035-30-1
• 化学式: C₂₂H₂₈N₂O₃
• 分子量: 368.476
• InChiKey: UDXNBALBEYWDRN-UHFFFAOYSA-N

物化性质

• 沸点：
  515.7±50.0 °C(Predicted)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  42
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-benzyloxyphenyl)piperazine-1-carboxylate 在 palladium 10% on activated carbon 、 氢气 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 1-对羟基苯基哌嗪
  参考文献：
  名称：

  [EN] MALIC ENZYME INHIBITORS
  [FR] INHIBITEURS D'ENZYME MALIQUE

  摘要：

  本发明涉及一种新型化合物，可用作苹果酸酶（ME）抑制剂，以及用于制备这些化合物的方法和利用这些化合物治疗由ME介导的疾病，如人类的癌症（例如胰腺导管腺癌（PDAC））。

  公开号：

  WO2021074898A1
• 作为产物：
  描述：

  氯化苄 在 potassium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 sodium t-butanolate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 27.0h， 生成 tert-butyl 4-(4-benzyloxyphenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Targeting Dopamine D₃ and Serotonin 5-HT_1A and 5-HT_2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies

  摘要：

  Combination of dopamine D-3 antagonism, serotonin 5-HT1A partial agonism, and antagonism at 5-HT2A leads to a novel approach to potent atypical antipsychotics. Exploitation of the original structureactivity relationships resulted in the identification of safe and effective antipsychotics devoid of extrapyramidal symptoms liability, sedation, and catalepsy. The potential atypical antipsychotic 5bb was selected for further pharmacological investigation. The distribution of c-fos positive cells in the ventral striatum confirmed the atypical antipsychotic profile of 5bb in agreement with behavioral rodent studies. 5bb administered orally demonstrated a biphasic effect on the MK801-induced hyperactivity at dose levels not able to induce sedation, catalepsy, or learning impairment in passive avoidance. In microdialysis studies, 5bb increased the dopamine efflux in the medial prefrontal cortex. Thus, 5bb represents a valuable lead for the development of atypical antipsychotics endowed with a unique pharmacological profile for addressing negative symptoms and cognitive deficits in schizophrenia.

  DOI：

  10.1021/jm501119j

文献信息

• BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION
  申请人：SANDANAYAKA Vincent

  公开号：US20070149544A1

  公开（公告）日：2007-06-28

  The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.

  本发明涉及一种化学类别的双芳基氮连接杂环的化合物，它们是LTA4H（白三烯A4水解酶）的抑制剂。这些化合物具有下列的一般式：它们可用于治疗、预防和预防炎症性疾病和疾患。
• Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation
  申请人：deCODE genetics ehf

  公开号：US07750012B2

  公开（公告）日：2010-07-06

  The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.

  本发明涉及一种化学类别的双芳基氮连接杂环的化合物，它们是LTA4H（白三烯A4水解酶）的抑制剂。这些化合物具有以下通式：它们可用于治疗、预防和预防炎症性疾病和疾病。
• Malic enzyme inhibitors
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LTD

  公开号：US11225480B2

  公开（公告）日：2022-01-18

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.

  本发明涉及可用作苹果酸酶（ME）抑制剂的新型化合物、其制备工艺以及这些化合物用于治疗由ME介导的疾病，如人类癌症（如胰腺导管腺癌（PDAC））。这些新型化合物具有符合式 I 的结构 或其药学上可接受的盐、立体异构体或氚代类似物，其中 X、R1、R2 和 Y 如本文所述。
• Synthesis and Characterization of a Novel Series of Agonist Compounds as Potential Radiopharmaceuticals for Imaging Dopamine D_2/3 Receptors in Their High-Affinity State
  作者：Jan-Peter van Wieringen、Vladimir Shalgunov、Henk M. Janssen、P. Michel Fransen、Anton G. M. Janssen、Martin C. Michel、Jan Booij、Philip H. Elsinga

  DOI：10.1021/jm401384w

  日期：2014.1.23

  Imaging of dopamine D-2/3 receptors (D2/3R) can shed light on the nature of several neuropsychiatric disorders in which dysregulation of D2/3R signaling is involved. Agonist D-2/3 tracers for PET/SPECT imaging are considered to be superior to antagonists because they are more sensitive to dopamine concentrations and may selectively label the high-affinity receptor state. Carbon-11-labeled D2/3R agonists have been developed, but these short-lived tracers can be used only in centers with a cyclotron. Here, we report the development of a series of novel D2R agonist compounds based on the 2-aminomethylchromane (AMC) scaffold that provides ample opportunities for the introduction of longer-lived [F-18] or [I-123]. Binding experiments showed that several AMC compounds have a high affinity and selectivity for D2/3R and act as agonists. Two fluorine-containing compounds were [18(F)]-labeled, and both displayed specific binding to striatal D2/3R in rat brain slices in vitro. These findings encourage further in vivo evaluations.
• In the Quest for Potent and Selective Malic Enzyme 3 Inhibitors for the Treatment of Pancreatic Ductal Adenocarcinoma
  作者：Gaurav Sheth、Shailesh R. Shah、Prabal Sengupta、Tushar Jarag、Sabbirhusen Chimanwala、Kalapatapu V. V. M. Sairam、Vaibhav Jain、Rashmi Talwar、Avinash Dhanave、Mehul Raviya、Soumya Menon、Shivangi Trivedi、Trinadha Rao Chitturi

  DOI：10.1021/acsmedchemlett.2c00369

  日期：2023.1.12